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In Turkey, Ankaferd Blood Stopper® (ABS) has been approved for the management of external haemorrhages and 
bleedings o ccurring during den tal surgeries (Goker et al., 200 8). A nkaferd co mprises a standardized m ixture of  plants,  
including Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica diodica. This stud y aimed to 
evaluate the ef ficacy of  AB S tam ponade in the contro l of  intra-oper ative b leeding occurring during ad enoidectomy 
performed in children under th e age of 12. Sixty  children were randomized to receive 1 to 5 m inute- tamponade with either  
ABS or  topical gauze spong es soaked in saline solution (SS)  d uring their ad enoidectomy.. Ti me-to-haemostasis and the 
number of packs required were recorded. A visual analog scale was used by the operating surgeon to record subjective data, 
including the rate of  bleeding following the f irst adenoid pack removal (0= none, 3=brisk). Co mpared to the child ren in the 
SS group (n=30), time-to-haemostasis seen in ABS patients (n=30) was significantly shorter (mean ± standard deviation, 1.93 
± 1.39 m in vs 3 .20 ± 1.50  min; p<0.0001); they required a lower  number of packs (m ean, 1.93  vs. 3.20), and appeared to 
bleed less (53.3% vs 6.7%; p=0.0001). ABS aids in the contro l of intra-operative bleeding and reduces the number of packs 
required to achieve h aemostasis, so th at it can be recommended f or tamponades per formed during  paediatric 
adenoidectomies. 
 






Ankaferd Blood Stopper ® (ABS) is a m edicinal plant extr act which has previously  been used  in the Turkish  
traditional medicine as a haemostatic agent (Huri et al, 2009; Kurt et al, 2008) . Previous reports as to the safety and efficacy 
of this product have indicated its sterility and non-toxicity (Cipil et al, 2009; Goker et al, 2008; Bilgili et al, 2009; Kurt et al, 
2009). In this study, the ef ficacy of ABS tamponade undertaken to contro l bleeding during ad enoidectomy, was com pared 




Materials and Methods 
 
A prospective, non-randomized, non-blinded observational study was condu cted in 60  consecutive children  who 
underwent adenoidectomy between March 2009 and May 2009.  Th e study was approved by  the local Bo ard of  Ethics. A 
written consent was obtained from the par ents of all pat ients prior to their inclusion. Each child was assigned either to the 
ABS or the SS group in order  of  appearan ce on the surgical waiting list. Th e pat ients wer e subj ected to the int ended 
procedure if having an upper airway obstruction due to adenoid tissue. Children younger than 3 or older than 12, and/or those 
suffering from haematological disorders, were excluded from the study.  
 All surger ies w ere perf ormed b y the sam e surgeon (H .Y.) under general anaesthesia achieved by  endotracheal 
intubation. Ac cording to our s tudy protocol, e ach pat ient was placed in the Rose po sition; a Davis-Boy le mouth gag 
supported by Draffin bipods was inserted in to the mouth. A tong ue retractor of  a suitab le size was used depend ing on the 
patient’s ag e. A denoidectomy was then p erformed us ing a  cur ette and  th e oper ative site w as p acked with  e ither an ABS  
tamponade or a saline-soaked sponge gauze for 1 m in. Following a g entle removal of the tamponade, the bleeding control 
efficacy was evaluated by the operating surgeon by means of a visual analog scale (0= none, 3= brisk). The tamponade was 
switched at 1 m in intervals, as r equired. Children who persistently  bled despite a 5 minute- tamponade were considered for 
additional haemostatic procedures (e.g. electrocauterisation).  
 Following the  a ttainment of  an absolute haemostasis, Dav is-Boyle mouth gag w as removed and  the patient was 
extubated. Acetaminophen was recommended for pain  relief  and administered as required. No antibiotics were prescrib ed 
routinely. The children  were ex amined for bleeding and  discharged on the f irst postoperative day. Data  were  analyzed by  










                No statistically significant differences in age and sex of  the children  c onstituting the two groups (p>0.05) we re 
revealed; the mean ages of the 30 children (19 male, 11 female) in the ABS group and the 30 children (16 male, 14 female) in 
the SS group we re 7.83 ± 3.17 yrs and 6.30 ± 2.56 yrs, respectively. In 16 ABS ( 53.3%) and two SS patients (6 .7%), intra-
operative haemostasis was achieved after a single pack application (p=0.0001, Table 1). In 88.9% members of the ABS group 
and 11.1% members of the SS group, tim e-to- haemostasis equalled to 1 minute, which is statistically significant (p=0.0001; 
Table 2). The mean num ber of packs used in the ABS group and the SS group was 1.93, and 3.20 , respectively (p=0.0001). 
Electrocauterisation was used to  achieve haemostasis in one child in the ABS group, and three children in the SS group. No 
major complications had been seen during or  after the surgery in either group; the same goes for early or late po stoperative 
bleedings or infections. 
 
Table 1: Subjective data recorded by the operating surgeon with regards to the rate of bleeding after the removal of the first 












Table 2: Comparison of time-to-haemostasis established in the two groups (p=0.0001, Chi-square test). ABS: Ankaferd 









                                    
 
 




Adenoidectomy is on e of  the m ost co mmonly perf ormed p rocedures in children , but b leeding f ollowing 
adenoidectomy may pose a s a c hallenge to a surgeon and  may require the  pl acement of  a post erior n asopharyngeal pack  
followed by a subsequent prolonged hospitalisation (Mathiasen and Cruz, 2004). Therefore, improvements in currently used 
techniques and innovations th at enable a m ore ef ficient bl eeding control dur ing and f ollowing adenoid ectomy would be 
welcomed.   
 An ideal haemostatic agent can be applied quickly, conveniently and accurately. It should work to stop even rap id 
bleeding from a vessel or organ without causing local injury or systemic effects. Furthermore, it should work equally well on 
the anticoagulated and  non- anticoagulated patie nt. Tradition al electrical and mechanical m eans are still the m ainstay of  
haemorrhage control, but new haemostatic technologies continue to emerge (de la Torre et al, 2007). Mechanical and active 
topical sealants and haemostatic agents are now available in different forms; these agents can be used in a variety of settings 
as adjuncts to the control of surgical bleeding (Spotnitz et al, 2007; Jo et al, 2007; Mathiasen and Cruz, 2004).  
 As an adjunctive treatment undertaken to the end of haemorrhage control, ABS can be used only  topically, and not 
systemically. It induces a rapid formation of an unique protein network in both plasm a and serum (Cipil et al, 200 9, Kurt et 
al, 2008) . Ther efore, this uniq ue m echanism of action provide s ABS with the advantage o ver other haemostatic p lant 
extracts. ABS  can be ef fective in subj ects with  norm al haem ostatic par ameters, as wel l as in those with prim ary and/or 
secondary haematological disorders (Cipil et al., 2008). In addition to the phy siological haemostatic process, ABS exposure 
appears to enab le an incr eased tissu e oxy genation without affecting any  individual clo tting f actor (Goker et  al, 2008) . 
Shortening of the bleeding duration ach ieved by the app lication of topical ABS, suggests that the extract functions, at least 
partly, via m odulation of  platelet f unctions (Cipil et al, 2008) . Other po ssible m echanisms of  its action r equire f urther 
elucidation.  
 In our study we observed a statistically significantly shorter duration of bleeding and a statistically lower number of 
packs required to achieve ABS tam ponade-induced haemostasis during adenoidectomy as com pared to saline-soaked gauze 
sponge application. However, there were certain limitations to this study. Firstly, ABS tamponade is a pack soaked by 10 ml 
of ABS solution, which was applied in all adenoidectomy cavities. The optimal dosage of ABS is not certain. Secondly, ABS 
ampoules that contain 2 ml of the agent may be more beneficial topically within the surgical field as a higher proportion may 




None 16 (53.3) 2 (6.7) 18 (30) 
Mild 8 (26.7) 9 (30) 17 (28.3) 
Moderate 2 (6.7) 11 (36.7) 13 (21.7) 








1 16 (88.9) 2 (11.1) 18 
2 8 (47.1) 9 (52.9) 17 
3 2 (15.4) 11 (84.6) 13 
4 1 (50) 1 (50) 2  
≥5  3 (30) 7 (70) 10 
Total 30 (50) 30 (50) 60 
doi: 10.4314/ajtcam.v8i4.16




be appropriately delivered in a more cost-effective manner. Thirdly, ABS is avail able in form of haemostatic spray which 
could be u seful for surgeries su ch as adeno idectomy. In conc lusion, f urther clinical stud ies ar e recommended in order to  
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